Galaxy Surfactants: Why you should accumulate this stock
With prospects tied to economic recovery, Galaxy may be looking at a turnaround09-12-2023
09-12-2023
Galaxy Surfactants Ltd - 540935 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate01-12-2023
Q2 results review: Galaxy Surfactants, Vinati Organics, other Specialty chemical firms may have a better second half
Q2 Result review- As companies weather destocking cycle, weak export demand and other challenges, the management commentaries post Q2 as per analysts indicate that destocking cycle may be coming to and end, China dumping may have slowed down and costs structures remain under check.20-11-2023
Galaxy Surfactants Ltd - 540935 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings Conference call for Q2 FY 2023-2416-11-2023
For Galaxy Impact of Inventory destocking cycle may be behind says Galaxy,s MD U Shekhar.
Q2 Results Review- Galaxy Surfactants consolidated Q2 net profit at 77.4 Crore grew 3% sequentially though was down 7.7% yoy. The volume growth remain stronger and Galaxy's MD expects growth momentum to continue in Q3 while the impact of Global destocking cycle may be behind.15-11-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Galaxy Surfactants Ltd.
Specialty Chemicals company Galaxy Surfactants announced Q2FY24 & H1FY24 results: Financial Performance: Total Revenue: Galaxy Surfactants reported a total revenue of Rs 1,930.1 crore for H1FY24. EBITDA: The company achieved an EBITDA of Rs 253.2 crore. PAT: The Profit After Tax (PAT) stood at Rs 152.6 crore. Operational Performance: Volume Growth: The company saw volume growth across all regions and segments in Q2FY24. India: There was a strong positive performance with an upward trend in volume growth. AMET (Africa Middle East and Turkey): There was a recovery in performance-surfactant volumes. ROW (Rest of the World): There was a low single-digit sequential improvement in Q2FY24. Sales Volume: Performance Surfactants: Maintained strong double-digit growth in H1FY24 and Q2FY24. Specialty Care: Masstige segments returned to growth with high single-digit volume growth YoY and double-digit growth in Q2FY24. Commenting on the performance U. Shekhar, Managing Director, Galaxy Surfactants said, “This has been a Good Quarter for us. Volume growth registered across all regions and segments in Q2FY24 is a strong positive. While the Profitability has declined marginally, across-the-board volume growth implies demand revival. India continues to remain a big positive for us. Easing inflation and macro issues in Africa Middle East, and Turkey have enabled strong performance-surfactant volume recovery. Barring any adverse spillover effects of the War, we do see this trend continuing. While Masstige specialties have done very well in India, AMET, and ROW, premium specialties continue to lag due to the inventory destocking situation in North America and recessionary conditions in Europe. But given the low single-digit sequential improvement seen in Q2FY24, we do expect a better 2024 for our premium specialties. Going ahead, barring any adverse supply-led shocks, volume growth should remain in the upper band of 6- 8%. Easing inflation and improvement in demand for premium specialties will gradually ensure improvement in EBITDA/MT from FY 2024-25.”13-11-2023
Galaxy Surfactants Ltd - 540935 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of Audio Recording of Investor concall.11-11-2023
Galaxy Surfactants Ltd - 540935 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for quarter and half year September 30,202310-11-2023
Galaxy Surfactants Ltd - 540935 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and half year ended September 30,202310-11-2023
Galaxy Surfactants Ltd - 540935 - Approval For Formation Of The Wholly Owned Subsidiary In Europe
Board of Directors at its meeting held on November 10, 2023 approved formation of wholly owned Subsidiary in Europe10-11-2023